ORLANDO, Fla. — The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) reduced cardiovascular events and reduced the risk of progression to diabetes by 73% in people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results